HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib
Guang Yang(Blueprint Medicines (United States)), Steven P. Treon(Dana-Farber Cancer Institute), Nathanael S. Gray(Stanford University), Jorge J. Castillo(Dana-Farber Cancer Institute), Zachary R. Hunter(Harvard University), Christopher J. Patterson(Dana-Farber Cancer Institute), Nicholas Tsakmaklis(Shaanxi Research Association for Women and Family), Sara J. Buhrlage(Harvard University), Jiaji G. Chen(Boston Medical Center), Shuai Liu(Tongji University), Jie Chen(Zhejiang Chinese Medical University), Xia Liu(Jiujiang University), Li Tan(Harvard University), Wei Zhang(University of Massachusetts Boston), Xiaofeng Zhang(Harvard University), Philip Cohen(MRC Protein Phosphorylation and Ubiquitylation Unit), Lian Xu(Huazhong Agricultural University), Jennifer R. Brown(Dana-Farber Cancer Institute)
Cited by 137
Related Papers
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
|Journal of Biological Chemistry|2009|1.8k